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We aimed to analyze the drug resistance patterns of multidrug-resistant and extensively 
drug-resistant tuberculosis (TB) and the difference of drug resistance among various set-
tings for health care in Korea. The data of drug susceptibility testing in 2009 was analyzed 
in order to secure sufficient number of patients from various settings in Korea. Patients 
were categorized by types of institutions into four groups, which comprised new and previ-
ously treated patients from public health care centers (PHC), the private sector, and Dou-
ble-barred Cross clinics (DBC). The resistance rates to first-line drugs were uniformly high 
in every group. While the resistance rates to second-line drugs were not as high as first-
line drugs, there was a pattern that drug resistance rates were lowest for PHC and highest 
for DBC. The differences of the resistance rates were more prominent for oral second-line 
drugs. Our findings implied that drug resistance to oral second-line drugs was significantly 
amplified during multidrug-resistant-TB treatment in Korea. Therefore, an individualized 
approach is recommended for treating drug-resistant-TB based on susceptibility testing 
results to prevent acquisition or amplification of drug resistance.
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The emergence of drug-resistant tuberculosis (DR-TB) is a ma-
jor obstacle for eradicating TB [1]. Multidrug-resistant TB (MDR-
TB) and extensively drug-resistant TB (XDR-TB) are well-known 
drug-resistant forms of TB that are difficult to treat [1, 2]. There-
fore, it is important to understand the drug resistance profiles of 
MDR- and XDR-TB for selecting an appropriate treatment regi-
men. In Korea, the rate of MDR-TB is increasing and a signifi-
cant proportion of MDR-TB patients are XDR-TB [3-5]. However, 
the resistance patterns of second-line drugs in Korea have been 
rarely reported, and results are not consistent. Therefore, the 
aim of this study was to analyze the drug resistance patterns of 
MDR-TB and XDR-TB and the differences of drug resistance 
between patient groups in Korea. 
In 2009, a total of 18,166 Mycobacterium tuberculosis isolates 
were referred to the Korean Institute of Tuberculosis (KIT) for 
drug susceptibility testing (DST), which is a supranational TB 
reference laboratory. After exclusion of duplicates, DST results 
of 16,860 TB patients were analyzed. Among those patients, 
5,137 (4,475 new patients and 662 previously treated patients) 
were from public health centers (PHC). The private sector ac-
counted for the largest proportion of patients (11,248, 66.7%). 
The treatment history of patients in the private sector could not 
be assessed because the isolates were referred to the KIT with-
out a medical history. In addition, 475 patients were from Dou-
ble-barred Cross (DBC) clinics, which belong to the Korean Na-
tional Tuberculosis Association and are dedicated to treating 
DR-TB or chronic TB patients. Because of the institutional char-
acteristics of DBC clinics, we assumed that patients of DBC 
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clinics would not be newly diagnosed TB patients and have a 
previous treatment history.
DST was performed by using the Lowenstein-Jensen absolute 
concentration method at the KIT [6]. The tested drugs and their 
critical concentrations were as follows: 0.2 and 1.0 µg/mL for 
isoniazid (INH); 40 µg/mL for rifampicin (RIF), kanamycin (KM), 
amikacin (AMK), capreomycin (CAP) and ethionamide (ETH); 
10 µg/mL for streptomycin (SM); 2 µg/mL for ethambutol (EMB) 
and ofloxacin (OFL); 1 µg/mL for para-aminosalicylic acid (PAS); 
30 µg/mL for cycloserine (CS); and 20 µg/mL for rifabutin (RBT). 
Resistance to pyrazinamide (PZA) was determined by using the 
pyrazinamidase assay (Wayne method) as described previously 
[7]. 
Multidrug resistance (resistance to both RIF and INH) was 
identified in 1,341 patients (8.0%). The prevalence of MDR-TB 
in new patients and previously treated patients of PHCs was 3.4% 
and 9.5%, respectively and that at the private sector and DBC 
clinics was 8.0% and 48.2%, respectively (Fig. 1). 
The overall drug resistance rate among the MDR-TB patients 
was highest in those from DBC clinics (Table 1). The resistance 
rates to first-line oral agents (high-level INH, RBT, EMB, and 
PZA) were uniformly high among the MDR-TB patients. RBT 
can be applicable to 28.7% of MDR-TB patients. However, the 
PZA resistance rates varied significantly across patient groups, 
ranging from 39.7% to 70.7% (P <0.001). The resistance rates 
to SM ranged from 20.6% to 34.4%, which were higher than 
those observed to other injectables. This is because SM was 
widely used as a first-line drug, whereas other injectables are 
mainly used for specifically treating MDR-TB patients. The re-
sistance rates to injectables, such as KM, AMK, and CAP, were 
lowest among the tested drugs. 
The MDR-TB patients showed relatively high resistance rates 
to OFL and Group 4 drugs (ETH, CS and PAS). In addition, dif-
ferences in the prevalence of resistance to those drugs were sta-
tistically significant between patient groups (P <0.001) (Table 1). 
Fig. 1. The prevalence of multidrug-resistant (MDR) tuberculosis 
(TB) and proportion of extensively drug-resistant (XDR)-TB among 
MDR-TB. 
Abbreviations: PHC new, public health center patients with newly diagnosed 
tuberculosis; PHC retreatment, public health center patients with previously 
treated tuberculosis; DBC, Double-barred Cross. 
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Table 1. Drug resistance in multidrug-resistant tuberculosis patients by patient group (n=1,341)
Drugs
PHC new (n=154) PHC retreatment (n=63) Private sector (n=895) DBC clinics (n=229)
P value*
R% (95% CI) R% (95% CI) R% (95% CI) R% (95% CI)
Isoniazid† 75.3 (68.5, 82.1) 71.4 (60.3, 82.6) 81.5 (78.9, 84.0) 78.2 (72.8, 83.5) 0.379
Rifabutin 71.4 (64.3, 78.6) 84.1 (75.1, 93.2) 70.2 (67.2, 73.2) 72.1 (66.2, 77.9) 0.085
Streptomycin 34.4 (26.9, 41.9) 20.6 (10.6, 30.6) 32.6 (29.6, 35.7) 32.8 (26.7, 38.8) 0.121
Ethambutol 58.4 (50.7, 66.2) 55.6 (43.3, 67.8) 68.2 (65.1, 71.2) 68.1 (62.1, 74.2) 0.14
Pyrazinamide 42.2 (34.4, 50.0) 39.7 (27.6, 51.8) 51.3 (48.0, 54.6) 70.7 (64.8, 76.6) <0.001
Kanamycin 10.4 (5.6, 15.2) 12.7 (5.5, 25.0) 17.7 (15.2, 20.2) 19.7 (14.5, 24.8) 0.227
Amikacin 9.1 (4.6, 13.6) 9.5 (3.5, 20.7) 14.9 (12.5, 17.2) 16.2 (11.4, 20.9) 0.299
Capreomycin 7.1 (3.1, 11.2) 6.3 (1.7, 16.3) 13.1 (10.9, 15.3) 16.6 (11.8, 21.4) 0.057
Ofloxacin 15.6 (9.9, 21.3) 14.3 (6.5, 27.1) 35.2 (32.1, 38.3) 61.1 (54.8, 67.4) <0.001
Ethionamide 15.6 (9.9, 21.3) 15.9 (6.8, 24.9) 28.0 (25.1, 31.0) 43.7 (37.2, 50.1) <0.001
Cycloserine 3.2 (1.1, 7.6) 4.8 (1.0, 13.9) 15.5 (13.2, 17.9) 26.6 (20.9, 32.4) <0.001
PAS 14.9 (9.3, 20.6) 15.9 (6.8, 24.9) 27.2 (24.2, 30.1) 33.2 (27.1, 39.3) 0.004
*Pearson’s chi-squared test was performed to evaluate the difference in resistance rates between patient groups. A P <0.05 was considered statistically sig-
nificant; †Higher concentration of isoniazid (1.0 µg/mL).
Abbreviations: R, resistance; CI, confidence interval; PHC new, public health center patients with new tuberculosis; PHC retreatment, public health center 
patients with previously treated tuberculosis; DBC, double-barred cross; PAS, para-aminosalicylate sodium.
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The resistance rates to OFL of private hospitals and DBC clinics 
were 2.3- and 3.9-times higher than those of new patients from 
the PHCs (Table 1). Similar drug resistance patterns were ob-
served to Group 4 drugs and OFL. The MDR-TB patients showed 
an 8.3-times higher rate of CS resistance compared with that of 
the new patients from PHCs. 
The proportion of XDR-TB among MDR-TB patients in Korea 
was highly variable in previous reports. Kim et al [2] reported 
that the proportion of XDR-TB among MDR-TB was 5.3%. How-
ever, in an analysis of the medical records of TB patients notified 
in 2008, Park et al [4] found that 18.8% of the MDR-TB patients 
were XDR-TB. Our analysis revealed that the proportion of XDR-
TB varies across patient groups. XDR-TB accounted for 12.3% 
(165) of the MDR-TB patients ranging from 4.5% in new patients 
of PHCs to 20.1% in DBC clinics (Fig. 1). MDR-TB patients di-
agnosed at PHCs were more likely to be new MDR-TB patients, 
and the patients were unlikely to have been previously exposed 
to a regimen for treating MDR-TB. By contrast, MDR-TB patients 
with a previous MDR-TB treatment history or chronic patients 
tend to visit specialized institutes, such as DBC clinics. The ma-
jority of the XDR-TB patients were resistant to first-line oral drugs 
(Table 2). However, the resistance rates to high-level INH and 
RBT were relatively low, indicating that these drugs should be 
considered first for XDR-TB treatment. Among the second-line 
injectables, the rate of resistance to KM was highest, and the 
rate of resistance to CAP was lowest in every patient group. There-
fore, OFL, EMB, PZA, and KM should not be included in empiri-
cal treatment regimens if XDR-TB is suspected. However, SM 
and CS could be the first option for treating XDR-TB because of 
the relatively low resistance rates to these drugs (44.8% and 
47.3%). Five of the XDR-TB patients demonstrated resistance 
to all tested drugs, which implies that these were pandrug-resis-
tant TB. 
Our study has a limitation that we didn’t include recent data 
for the analysis. We aimed to reveal the differences of drug re-
sistance patterns according to types of institutions. However, TB 
patients notified in the private sector outnumber those in the 
public sector in Korea [8, 9]. This trend has been accelerated 
because the Korean National Insurance System increased fi-
nancial support for TB patients. Actually, more than 90% of TB 
patients were notified from the private sector in 2016 [9]. As a 
result, more than a half of DBC clinics have been closed since 
2010 and the number of patients greatly declined recently. There-
fore, we decided to use DST data from a year of 2009 to analyze 
sufficient number of patients for each group.
The private sector plays a major role in the programmatic man-
agement of DR-TB (PMDT) in Korea [8]. The majority of DR-TB 
patients are treated in the private sector because capacity of the 
public sector is limited to treat DR-TB. However, TB care in the 
private sector is often of poor quality owing to a lack of standard-
ization and regulation [8, 10, 11]. Thus, it is well documented 
that the risk of developing resistance to anti-TB drugs is higher 
in the private sector [11]. Therefore, it is important to analyze 
drug resistance patterns in both the public and private sector to 
best combat DR-TB. The previous reports on drugs resistance 
in the MDR-TB patients were unable to reflect the overall drug 
resistance status in Korea because such analyses were often 
conducted in only one sector or in a small population [2, 4]. In 
the present study, the drug resistance patterns were separately 
analyzed for a large number of the MDR-TB patients from vari-
ous patient groups. 
The resistance rates to the first-line drugs were high in the 
MDR-TB patients from all patient groups, suggesting that the 
prescription of these drugs should be considered carefully ac-
cording to the DST results. In contrast, the rates of resistance to 
second-line drugs varied substantially among the patient groups. 
The drug resistance rates to second-line drugs were lowest in 
the PHC patients and highest in those from DBC clinics. In ad-
dition, huge differences in drug resistance between patient groups 
were observed. This trend was more prominent for second-line 
oral agents, implying that the acquisition of resistance to sec-
ond-line oral agents could be common during the treatment of 
Table 2. Drug resistance in multidrug-resistant (MDR) and exten-
sively drug-resistant (XDR) tuberculosis patients
Drugs
MDR-TB (n=1,341) XDR-TB (n=164)
R% (95% CI) R% (95% CI)
Isoniazid* 79.7 (77.6, 81.9) 79.4 (73.2, 85.6) 
Rifabutin 71.3 (68.9, 73.7) 70.3 (63.3, 77.3) 
Streptomycin 32.3 (29.8, 34.8) 44.8 (37.3, 52.4) 
Ethambutol 66.4 (63.9, 69.0) 92.7 (88.8, 96.7) 
Pyrazinamide 53.0 (50.3, 55.7) 90.9 (86.5, 95.3) 
Kanamycin 16.9 (14.9, 18.9) 91.5 (87.3, 95.8) 
Amikacin 14.2 (12.3, 16.0) 77.6 (71.2, 83.9) 
Capreomycin 12.7 (10.9, 14.5) 69.1 (62.0, 76.1) 
Ofloxacin 36.4 (33.8, 39.0) 100 (NA) 
Ethionamide 28.7 (26.3, 31.1) 76.4 (69.9, 82.8 ) 
Cycloserine 15.5 (13.6, 17.4) 47.3 (39.7, 54.9) 
PAS 26.2 (23.9, 28.6) 70.3 (63.3, 77.3) 
*Higher concentration of isoniazid (1.0 µg/mL).
Abbreviations: R, resistance; CI, confidence interval; NA, not available; PAS, 
para-aminosalicylate sodium.
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MDR-TB. The patients of DBC clinics were resistant to more 
drugs than those of PHCs (8.0 vs 5.6 on average). Our results 
revealed that drug resistance of MDR-TB patients appears to 
have been amplified especially for second-line oral drugs be-
cause the likelihood of previous MDR-TB treatment was associ-
ated with higher drug resistance rates and increased number of 
resistant drugs. Fluoroquinolones (FQs) are the key drugs used 
for treating MDR-TB, and FQ resistance is closely related to a 
poor treatment outcome for MDR-TB [12]. Therefore, increas-
ing FQ resistance is a serious threat to PMDT. 
There are no specific treatment guidelines for XDR-TB, but 
the number of effective drugs is critical for treatment success 
[11, 13]. The treatment regimen for XDR-TB could be designed 
according to a drug resistance survey or surveillance data. How-
ever, our results showed that XDR-TB patients from Korea had 
high rates of resistance to most anti-TB drugs. Therefore, an in-
dividualized approach is highly recommended to treat XDR-TB 
based on the DST results and the patient’s drug prescription 
history. Additional DST for Group 5 drugs may be needed to find 
available drugs for treating XDR-TB. 
The poor management of DR-TB in Korea could results in the 
development of a more serious form of DR-TB. In fact, five of 
the XDR-TB patients were found to be resistant to all tested drugs. 
Fortunately, there are new options for treating DR-TB. Two new 
anti-TB drugs, delamanid and bedaquiline, are available, and 
repurposed anti-TB drugs showed good activity against TB [11]. 
However, we will likely face resistance to these new drugs and 
repeat the past without their proper and careful administration. 
The present study highlights the importance of aligning DST and 
treatment for DR-TB, and the need for strengthening PMDT.
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